This story has been updated from a previous version for content and clarity.
NEW YORK – A group of European researchers led by the Cancer Research UK Cambridge Institute has developed an analytical method to improve the detection of circulating tumor DNA (ctDNA) by tracking large numbers of patient-specific cancer mutations, a method which the team believes could be used for minimal residual disease (MRD) and cancer recurrence testing.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
